A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
2019 · Blood · 454 citations
https://doi.org/10.1182/blood-2018-10-881961
D
David F. Claxton
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
359
Papers
14.8K
Citations
52
h-index
152
i10-index
David F. Claxton is an academic researcher from Pennsylvania State University. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Hematopoietic Stem Cell Transplantation & Chronic Myeloid Leukemia Treatments. The author has an h-index of 52, co-authored 306 publications.
ORCID: 0000-0001-9209-2405Papers by this author
worksT-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
2016 · Clinical Cancer Research · 288 citations
https://doi.org/10.1158/1078-0432.ccr-15-2626
PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
2015 · Blood Cancer Journal · 140 citations
https://doi.org/10.1038/bcj.2015.58
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
2013 · Journal of Hematology & Oncology · 94 citations
https://doi.org/10.1186/1756-8722-6-81
Acid ceramidase is upregulated in AML and represents a novel therapeutic target
2016 · Oncotarget · 93 citations
https://doi.org/10.18632/oncotarget.13079
Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation
2019 · Journal of Lipid Research · 49 citations
https://doi.org/10.1194/jlr.m091876
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat